Conclusions
Tumor expression of genes related to extent of drug exposure can predict outcomes after chemotherapy treatment.
•High EGR1 and FOS mRNA independently predict response to FOLFOX in patients with wild-type p53 tumors.
•Low CCNB1 mRNA correlates with good prognosis of CRC patients with tumors harboring TP53LOF mutations.
•Gene signatures may demonstrate enhanced predictive ability as compared to individual transcript effects.
•MSI status impacts the predictive of BTG2.